ADA lentiviral vector-transduced hematopoietic stem cell gene therapy (Fondazione Telethon)

N/A

Report date: 2025/01/26 15:48:20

Base Information

Drug NameADA lentiviral vector-transduced hematopoietic stem cell gene therapy (Fondazione Telethon)
Drug Alias Namelentiviral vector mediated hematopoietic stem progenitor cell (HSPCs) gene therapy (Fondazione Telethon)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionADA gene transference
TargetsAdenosine deaminase
Therapy Area/IndicationsAdenosine deaminase deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFondazione Telethon
China Registration ClassN/A

Develop Information

Active CompaniesFondazione Telethon
Inactive CompaniesN/A
Active IndicationsAdenosine deaminase deficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A